• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

烟曲霉中 G448S 取代导致对伏立康唑耐药的脑曲霉病患者。

Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis.

机构信息

Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.

出版信息

J Clin Microbiol. 2012 Jul;50(7):2531-4. doi: 10.1128/JCM.00329-12. Epub 2012 May 9.

DOI:10.1128/JCM.00329-12
PMID:22573589
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3405584/
Abstract

A voriconazole-resistant isolate of Aspergillus fumigatus was recovered from an immunocompetent patient receiving long-term antifungal therapy for cerebral aspergillosis. A G448S amino acid substitution in the azole target (Cyp51A) was identified as the cause of the resistance phenotype. This article describes the first isolation of a voriconazole-resistant A. fumigatus isolate from an immunocompetent patient in Spain.

摘要

从一名接受长期抗真菌治疗脑曲霉病的免疫功能正常的患者中分离出了一株伏立康唑耐药的烟曲霉。唑类药物靶标（Cyp51A）中的 G448S 氨基酸取代被确定为耐药表型的原因。本文描述了首例从西班牙免疫功能正常的患者中分离出伏立康唑耐药的烟曲霉的情况。

相似文献

1
Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis.烟曲霉中 G448S 取代导致对伏立康唑耐药的脑曲霉病患者。
J Clin Microbiol. 2012 Jul;50(7):2531-4. doi: 10.1128/JCM.00329-12. Epub 2012 May 9.
2
Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma.患者肺曲霉菌病中出现对伏立康唑和伊曲康唑的获得性耐药。
Med Mycol. 2010 Feb;48(1):197-200. doi: 10.3109/13693780902717018.
3
In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus.烟曲霉中由于 G448S 突变（cyp51A 基因）导致伏立康唑耐药的体外-体内相关性。
Diagn Microbiol Infect Dis. 2012 Nov;74(3):272-7. doi: 10.1016/j.diagmicrobio.2012.06.030. Epub 2012 Aug 14.
4
In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.烟曲霉对伊曲康唑、伏立康唑和泊沙康唑的体外药敏性：与伏立康唑的相关性。
Antimicrob Agents Chemother. 2013 Nov;57(11):5778-80. doi: 10.1128/AAC.01141-13. Epub 2013 Sep 16.
5
Azole preexposure affects the Aspergillus fumigatus population in patients.唑类药物暴露前处理会影响烟曲霉种群在患者中的状态。
Antimicrob Agents Chemother. 2012 Sep;56(9):4948-50. doi: 10.1128/AAC.05990-11. Epub 2012 Jun 18.
6
Insight into the Significance of Aspergillus fumigatus cyp51A Polymorphisms.曲霉属烟曲霉 CYP51A 多态性的意义解析。
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00241-18. Print 2018 Jun.
7
Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole.烟曲霉中细胞色素 P45051A 基因突变株并不总是表现出对伊曲康唑、伏立康唑或泊沙康唑的表型耐药性。
Antimicrob Agents Chemother. 2011 May;55(5):2460-2. doi: 10.1128/AAC.01358-10. Epub 2011 Feb 14.
8
Fatal invasive pulmonary and cerebral aspergillosis due to triazole-resistant Aspergillus fumigatus with multiple CYP51A mutations.由具有多个CYP51A突变的三唑耐药烟曲霉引起的致命性侵袭性肺曲霉病和脑曲霉病。
J Antimicrob Chemother. 2024 May 2;79(5):1191-1192. doi: 10.1093/jac/dkae038.
9
Detection of Polish clinical Aspergillus fumigatus isolates resistant to triazoles.波兰临床分离的烟曲霉对三唑类药物耐药性的检测
Med Mycol. 2018 Jan 1;56(1):121-124. doi: 10.1093/mmy/myx012.
10
Molecular Characterization of a Voriconazole-Resistant, Posaconazole-Susceptible Aspergillus fumigatus Isolate in a Lung Transplant Recipient in the United States.美国一名肺移植受者中一株对伏立康唑耐药、对泊沙康唑敏感的烟曲霉分离株的分子特征分析
Antimicrob Agents Chemother. 2015 Nov 16;60(2):1129-33. doi: 10.1128/AAC.01130-15. Print 2016 Feb.

引用本文的文献

1
Understanding the clinical and environmental drivers of antifungal resistance in the One Health context.在“同一健康”背景下理解抗真菌药物耐药性的临床和环境驱动因素。
Microbiology (Reading). 2024 Oct;170(10). doi: 10.1099/mic.0.001512.
2
Azole resistance mechanisms and population structure of the human pathogen on retail plant products.唑类耐药机制与人类病原体在零售植物产品中的种群结构。
Appl Environ Microbiol. 2024 May 21;90(5):e0205623. doi: 10.1128/aem.02056-23. Epub 2024 Apr 23.
3
Selection of isolates carrying the G448S substitution in 51A gene after long-term treatment with voriconazole in an immunocompromised patient.在一名免疫功能低下患者长期使用伏立康唑治疗后，对携带51A基因G448S替代突变的分离株进行筛选。
Med Mycol Case Rep. 2022 Feb 18;36:5-9. doi: 10.1016/j.mmcr.2022.02.002. eCollection 2022 Jun.
4
Point Mutation or Overexpression of Aspergillus fumigatus Encoding Lanosterol 14α-Sterol Demethylase, Leads to Triazole Resistance.点突变或过表达烟曲霉编码角鲨烯 14α-甾醇脱甲基酶，导致唑类药物耐药。
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0125221. doi: 10.1128/AAC.01252-21. Epub 2021 Jul 26.
5
and aspergillosis: From basics to clinics.以及曲霉病：从基础到临床
Stud Mycol. 2021 May 10;100:100115. doi: 10.1016/j.simyco.2021.100115. eCollection 2021 Sep.
6
Hospital Environment as a Source of Azole-Resistant Strains with TR34/L98H and G448S Cyp51A Mutations.作为具有TR34/L98H和G448S Cyp51A突变的唑类耐药菌株来源的医院环境。
J Fungi (Basel). 2021 Jan 2;7(1):22. doi: 10.3390/jof7010022.
7
Characterization of cross-resistance between clinical and DMI azole drugs.临床用唑类药物与去甲基化抑制剂类唑类药物之间交叉耐药性的特征分析
Appl Environ Microbiol. 2021 Mar 1;87(5). doi: 10.1128/AEM.02539-20. Epub 2020 Dec 18.
8
A Cyp51B Mutation Contributes to Azole Resistance in .一种Cyp51B突变导致……中的唑类抗性 。 （注：原文不完整，翻译后的内容也存在信息不完整的情况）
J Fungi (Basel). 2020 Nov 26;6(4):315. doi: 10.3390/jof6040315.
9
The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens.耐药性侵袭性真菌病原体悄无声息且未得到充分重视的崛起
J Fungi (Basel). 2020 Aug 18;6(3):138. doi: 10.3390/jof6030138.
10
Anti-fungal activity of a novel triazole, PC1244, against emerging azole-resistant Aspergillus fumigatus and other species of Aspergillus.新型三唑化合物 PC1244 对新兴唑类耐药烟曲霉和其他曲霉属真菌的抗真菌活性。
J Antimicrob Chemother. 2019 Oct 1;74(10):2950-2958. doi: 10.1093/jac/dkz302.

本文引用的文献

1
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009.2007-2009 年荷兰烟曲霉唑类耐药的临床意义。
Emerg Infect Dis. 2011 Oct;17(10):1846-54. doi: 10.3201/eid1710.110226.
2
Aspergillosis in the 'nonimmunocompromised' host.非免疫功能低下宿主中的曲霉菌病。
Immunol Invest. 2011;40(7-8):751-66. doi: 10.3109/08820139.2011.614307.
3
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.奥地利、丹麦和西班牙的唑类耐药烟曲霉和其他曲霉的环境研究。
Antimicrob Agents Chemother. 2010 Nov;54(11):4545-9. doi: 10.1128/AAC.00692-10. Epub 2010 Aug 30.
4
Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009.烟曲霉唑类抗药性：2008 年和 2009 年。
J Antimicrob Chemother. 2010 Oct;65(10):2116-8. doi: 10.1093/jac/dkq279. Epub 2010 Aug 20.
5
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).CLSI 肉汤微量稀释法（M38-A2 文件）中三唑类药物和六种曲霉菌属的野生型 MIC 分布和流行病学折点值。
J Clin Microbiol. 2010 Sep;48(9):3251-7. doi: 10.1128/JCM.00536-10. Epub 2010 Jun 30.
6
Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence.唑类药物治疗期间烟曲霉对唑类药物耐药性的发展与毒力变化有关。
PLoS One. 2010 Apr 9;5(4):e10080. doi: 10.1371/journal.pone.0010080.
7
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).器官移植受者中的侵袭性真菌感染：移植相关感染监测网络（TRANSNET）的结果。
Clin Infect Dis. 2010 Apr 15;50(8):1101-11. doi: 10.1086/651262.
8
Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma.患者肺曲霉菌病中出现对伏立康唑和伊曲康唑的获得性耐药。
Med Mycol. 2010 Feb;48(1):197-200. doi: 10.3109/13693780902717018.
9
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?烟曲霉中的唑类抗性：环境中使用杀菌剂的副作用？
Lancet Infect Dis. 2009 Dec;9(12):789-95. doi: 10.1016/S1473-3099(09)70265-8.
10
Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.烟曲霉中唑类耐药与治疗失败相关的频率及演变
Emerg Infect Dis. 2009 Jul;15(7):1068-76. doi: 10.3201/eid1507.090043.